source
- Gate Bioscience eyes clinic trials with molecular gate drugs, backed by expanded $870M Lilly partnershipGate Bioscience is developing small-molecule drugs that block the Sec61 channel, preventing disease-causing proteins from entering cells and leading to their degradation. The company's first discl…
- Charles River acquires two Frontage bioanalysis labs in Pennsylvania for $470 millionCharles River Laboratories announced it has purchased two laboratory sites from Tigermed’s Frontage in Exton, Pennsylvania, paying $470 million upfront. The labs together span about 150,000 square…